valuations competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions insider buying – the “smart money” – can also be an indicator to evaluate the potential performance of a company biorestorative therapies inc brtx “biorestorative” insiders are expressing their confidence in the companys future dale broadrick an insider of the company has demonstrated this faith by acquiring 1000 shares of biorestorative these purchases were made at a price of an average of 280 per share on july 27 2023 as a result broadrick now owns a total of 623404 shares of the company it is worth noting that this transaction was executed through multiple trades with prices ranging from 275 to 285 per share the reported price of 280 represents the weighted average purchase price furthermore the company filed an sec form 4 following this transaction additionally the current ceo of brtx lance alstodt recently displayed additional confidence in the company by acquiring 4200 brtx shares as well insider stock purchases can provide valuable insights into the overall confidence and sentiment surrounding a company when insiders – such as executives or employees – purchase shares of their own company it often indicates a positive outlook on its future performance insiders have access to nonpublic information about the company including its financial health product pipeline and business strategies therefore their decision to purchase shares can be seen as a strong vote of confidence in the companys prospects biorestorative is a clinicalstage company specializing in stem cellbased therapies biorestorative’s leading product and novel drug brtx100 is an autologous stem cell product that uses the patient’s own stem cells which are harvested cultured under hypoxic conditions to maximize cell survivability and then injected directly into the patient’s body brtx100 is a noninvasive treatment and the procedure is a single intradiscal injection that takes approximately 15 minutes brtx100 is a promising treatment for chronic back pain as there are limited safety risks and human data from similar studies show promising results with reduced pain and increased function for millions of americans suffering without adequate treatment biorestorative’s innovative therapies might be the light at the end of the tunnel biorestorative’s other product – thermostem – has also shown promising results in the treatment of obesity and related diseases these recent developments highlight the growing interest and confidence among investors in biorestorative therapies inc as the company continues to make strides in the biotech industry biorestorative seems wellpositioned to excel in the stem cell market and become a leading player in a growing market with the global mesenchymal stem cell market expected to grow at a cagr of 128 from 2023 to 2030 read more about biorestorative’s trials and platform technology this post contains sponsored content this content is for informational purposes only and not intended to be investing advice